Science & Military2020-05-23
A Chinese lawmaker has suggested improving the country's medical science capacity to prevent epidemics at this year's Two Sessions. Dr. Ding Lieming from the pharmaceutical industry said that the science sector should be more involved in dealing with public health emergencies.Dr. Ding Lieming has been a national lawmaker for seven years and is now serving his second term. Since COVID-19 struck the country, he has been leading his company in east China's Hangzhou City to develop drugs and vaccines to fight it.
Chinese lawmaker Dr. Ding Lieming, chairman of Betta Pharmaceuticals, in an interview with CGTN reporter Wu Guoxiu about his suggestions for the 2020 Two Sessions. /CGTN
He said that although Chinese scientists isolated and fully sequenced the virus in a short time and shared the information with the world, other researches of the virus could have been faster. So, he is suggesting that China improve its innovative ability in medical science."Looking back, our scientific research on the virus was still a little bit slow, especially in the early period, how the virus triggered the sickness, how infectious it was... we need to improve our scientific innovation capability," Ding said.
For years, his company has produced new and innovative medications for malignant tumors and diabetes. He thinks China needs to do a better job of storing emergency materials, including medicines, at regional levels throughout the country.
"Emergency drugs should be stored not only for epidemics. When delivery services were suspended, many patients including cancer patients faced many difficulties in getting drugs. So all regions need to store emergency drugs and materials," he stressed.
China's central leadership has ordered a shoring up of weak spots in the public health sector. Dr. Ding believes the country needs a top level design for a scientific defense system against public health emergencies, with stronger technology, better facilities and effective team building.
Incomplete statistics from the National Health Commission show that China now has more than 200 national lawmakers and political advisors from the health sector. They are mostly drug developers, scientists, doctors and nurses. They are those who know where efforts should be strengthened in COVID-19 control, and who are eager to bring problems and solutions to the table at the Two Sessions.